Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01655225 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3023414 in Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 156
- Enrollment target
NCT01655225: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT01655225 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 156 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (160% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01655225, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 156 participants
- Enrollment target
Study Summary
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Midazolam
- DRUG Fulvestrant
- DRUG LY3023414
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2012-07-31 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 1 |
What the finished NCT01655225 record still lists
NCT01655225 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (160% higher).
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT01655225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01655225 about?
NCT01655225 is a clinical study titled "A Study of LY3023414 in Participants With Advanced Cancer". The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will h...
What is the current status of trial NCT01655225?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2012-07-31. Estimated completion is 2022-02-02.
What interventions are being tested in trial NCT01655225?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Midazolam (DRUG), Fulvestrant (DRUG), LY3023414 (DRUG).
Who is sponsoring clinical trial NCT01655225?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01655225's enrollment target sits among peer trials
156 351st of 2000 higher than 1,649 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI